CEO Lars Fruergaard Jorgensen discusses Wegovy
They have been a few rocky months to Novo Nordisk. IQVIA prescription data suggest that the Novo Wegovy Obesity Medication…
Novo Nordisk A/S
Novo Nordisk Ozempic wins FDA approval for chronic kidney disease
Food and medication administration approved Tuesday Novo Nordisk'S Ozempic to treat chronic kidney disease in patients who also have type…
Foods like new medical companies could benefit
Robert Kennedy Jr., nominated for the president of the United States, Donald Trump, to direct the Department of Health and…
Mergers and acquisitions in biotech and pharmaceuticals will recover in 2025
The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) on December 5, 2023. New York Stock Exchange Group…
GLP-1 and the murder of Brian Thomson gain importance at JPM Health
Jamie Dimon, CEO of JPMorgan Chase & Co., at the Institute of International Finance (IIF) during the IMF and World…
Eli Lilly LLY cuts 2024 revenue outlook for weight-loss drugs
The Eli Lilly & Co. logo at the company's Digital Health Innovation Hub facility in Singapore, Thursday, Nov. 14, 2024.…
Eli Lilly CEO Hopes New Weight-Loss Pill Approved Next Year
David Ricks, CEO of Eli Lilly Scott Mlyn | CNBC Eli Lilly It expects its experimental weight-loss pill to be…
High-cost weight-loss drugs drive nutritional counseling to employers
Wegovy, Ozempic and Mounjaro weight loss medication packages. Image Alliance | fake images A few years ago, when Virta Health…
Eli Lilly's lead in the obesity race has increased. Its recent stock performance says otherwise.
Eli Lilly investors have received some very good news in recent months, with one notable exception regarding the stock's performance.…
Medicare May Cover Eli Lilly's Zepbound for Sleep Apnea: Health Department Agency
An injectable pen of Zepbound, Eli Lilly's weight loss drug, is on display in New York City on December 11,…